ESMO Lung Cancer 2022 – Noemi Reguart

Noemi Reguart outlines if EGFR-directed treatment in the setting of advanced NSCLC should be based on T790M monitoring in clinical practice, outlines recent insights gained in the negative CANOPY-A trail using the anti-IL-1β antibody canakinumab after resection of early-stage NSCLC and summarizes the current treatment landscape in Europe with respect to small-cell lung cancer.

Here is the full ESMO 2022 Lung Cancer report.

More posts